Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Heike K. Wentsch"'
Publikováno v:
Organic Process Research & Development. 25:1831-1840
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bea11f7491d5859a16e89a22dcc93f95
https://doi.org/10.1021/acs.oprd.1c00081
https://doi.org/10.1021/acs.oprd.1c00081
Autor:
Silke M. Bauer, Eva Döring, Mike Bührmann, Adrian Sievers-Engler, Svenja C. Mayer-Wrangowski, R.C. Buijsman, Michael Lämmerhofer, Guido J.R. Zaman, Niklas M. Walter, Stefan Laufer, Heike K. Wentsch, Nicole Willemsen-Seegers, Daniel Rauh
Publikováno v:
Journal of Medicinal Chemistry. 60:8027-8054
We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo. However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79298a76844c625d9a2191f694192f81
https://doi.org/10.1021/acs.jmedchem.7b00745
https://doi.org/10.1021/acs.jmedchem.7b00745
Autor:
Heike K. Wentsch, Daniel Dauch, Mike Bührmann, Melanie Henning, Nicole Willemsen-Seegers, Stefan Laufer, Lars Zender, Rogier C. Buijsman, Svenja C. Mayer-Wrangowski, Guido J.R. Zaman, Niklas M. Walter, Daniel Rauh
Publikováno v:
Angewandte Chemie. 129:5448-5453
Vor kurzem wurde mit Skepinone-L ein p38α-MAP-Kinase-Inhibitor mit hoher Potenz und ausgezeichneter Selektivitat in vitro und in vivo beschrieben. Der Bindemodus dieser Substanzklasse entspricht allerdings dem eines ATP-kompetitiven Typ-I-Inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee7aa5aaabd8415d05a8b0d25108c045
https://doi.org/10.1002/ange.201701185
https://doi.org/10.1002/ange.201701185
Autor:
Niklas M, Walter, Heike K, Wentsch, Mike, Bührmann, Silke M, Bauer, Eva, Döring, Svenja, Mayer-Wrangowski, Adrian, Sievers-Engler, Nicole, Willemsen-Seegers, Guido, Zaman, Rogier, Buijsman, Michael, Lämmerhofer, Daniel, Rauh, Stefan A, Laufer
Publikováno v:
Journal of medicinal chemistry. 60(19)
We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo. However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7be2ea38043336115e8cb789d75c5e5e
https://pubmed.ncbi.nlm.nih.gov/28834431
https://pubmed.ncbi.nlm.nih.gov/28834431
Autor:
Guido J.R. Zaman, Stefan Laufer, Lars Zender, Melanie Henning, Svenja C. Mayer-Wrangowski, Daniel Rauh, Heike K. Wentsch, Daniel Dauch, R.C. Buijsman, Mike Bührmann, Nicole Willemsen-Seegers, Niklas M. Walter
Publikováno v:
Angewandte Chemie (International ed. in English). 56(19)
Skepinone-L was recently reported to be a p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo. However, this class of compounds still act as fully ATP-competitive Type I binders which, furthermore, suffer from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1be6d1dbc078e4a9c66ba3050e2892d6
https://pubmed.ncbi.nlm.nih.gov/28397331
https://pubmed.ncbi.nlm.nih.gov/28397331
Autor:
Stefan Fischer, Christian Grütter, Stefan Laufer, Silke M. Bauer, Daniel Rauh, Solveigh C. Koeberle, Kirsten Storch, Svenja C. Mayer-Wrangowski, Frank M. Boeckler, Heike K. Wentsch, Markus O. Zimmermann, Raimund Niess
Publikováno v:
Journal of Medicinal Chemistry. 56:241-253
p38α mitogen-activated protein (MAP) kinase is a main target in drug research concerning inflammatory diseases. Nevertheless, no inhibitor of p38α MAP kinase has been introduced to the market. This might be attributed to the fact that there is no i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e17fb412e5cb0930f41132ad98c8edf8
https://doi.org/10.1021/jm301539x
https://doi.org/10.1021/jm301539x